Cartesian Therapeutics (RNAC) Shares Outstanding (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Shares Outstanding data on file, last reported at $28.5 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $28.5 million, up 10.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (up 10.06% YoY), and the FY2025 annual result was $26.0 million, up 0.95% from the prior year.
• Shares Outstanding improved to $28.5 million in Q1 2026 per RNAC's latest filing, from $26.0 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $153.0 million in Q3 2022 and troughed at $5.1 million in Q4 2022.
• A 5-year average of $38.9 million and a median of $25.8 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding slumped 96.65% in 2023, then surged 377.39% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $5.1 million in 2022, then grew by 5.8% to $5.4 million in 2023, then jumped by 377.39% to $25.8 million in 2024, then grew by 0.95% to $26.0 million in 2025, then grew by 9.74% to $28.5 million in 2026.
• Business Quant data shows RNAC's Shares Outstanding at $28.5 million in Q1 2026, $26.0 million in Q4 2025, and $26.0 million in Q3 2025.